Vaxart Inc. (VXRT)
0.39
0.04 (11.43%)
At close: Apr 03, 2025, 3:59 PM
0.38
-1.94%
Pre-market: Apr 04, 2025, 04:05 AM EDT
11.43% (1D)
| Bid | 0.37 |
| Market Cap | 87.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | -1.17 |
| Forward PE | -1.79 |
| Analyst | Buy |
| Ask | 0.42 |
| Volume | 2,552,227 |
| Avg. Volume (20D) | 1,902,470 |
| Open | 0.35 |
| Previous Close | 0.35 |
| Day's Range | 0.34 - 0.41 |
| 52-Week Range | 0.34 - 1.30 |
| Beta | 1.57 |
About VXRT
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the t...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 1981
Employees 105
Stock Exchange NASDAQ
Ticker Symbol VXRT
Website https://vaxart.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VXRT stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 679.02% from the latest price.
Stock ForecastsNext Earnings Release
Vaxart Inc. is scheduled to release its earnings on May 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+1.5%
Vaxart shares are trading higher after the company...
Unlock content with
Pro Subscription
7 months ago
+25.66%
Vaxart shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $4 price target.
